Investment Rating - The industry rating is maintained at "Overweight" [2][10] Core Insights - The vaccine industry is transitioning from scale expansion to innovation-driven growth, facing short-term pain due to supply-demand imbalance and homogenized competition, but the long-term outlook remains positive driven by policy, demand, and technology [10][30] - The "14th Five-Year Plan" emphasizes high-quality development and full lifecycle immunization opportunities for the vaccine industry, indicating a shift towards a comprehensive immunization service system covering all age groups [4][10] - The industry is experiencing performance differentiation among companies, with a focus on innovative vaccines and multi-valent products to enhance competitiveness [9][10] Market Performance - The vaccine sector saw a 1.29% increase last week, while the overall pharmaceutical sector declined by 0.22% [5][12] - Year-to-date, the vaccine sector has experienced a cumulative decline of 13.18% [5][12] Valuation Metrics - The vaccine sector's PE (ttm) is 65.37X, down 1.47X week-on-week, with a one-year range of 31.95X to 111.89X [8][23] - The PB (lf) stands at 1.21X, a decrease of 0.03X from the previous week, with a one-year range of 1.66X to 2.15X [8][23] Investment Recommendations - The vaccine industry is under pressure, with performance still in a bottoming phase; however, companies are adjusting their pipeline strategies to focus on technological innovation and new vaccine development [9][27] - Long-term focus should be on companies with strong R&D capabilities and differentiated product offerings, with a recommendation to pay attention to companies like CanSino [10][30]